In the last decade, the prognosis and treatment of non-small-cell lung cancer (NSCLC) have improved as a result of the discovery of epidermal growth factor receptor (EGFR) mutations, which are predictor markers for the response to tyrosine kinase inhibitors (TKIs). Here, EGFR is linked to non-small cell lung carcinoma.